The top 10 CMOs in India: Market Dynamics, Competitive Positioning and Trends

Date: October 22, 2010
Pages: 107
Price:
US$ 3,835.00
Publisher: Business Insights
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: T00107FEDDBEN
Leaflet:

Download PDF Leaflet

The top 10 CMOs in India: Market Dynamics, Competitive Positioning and Trends
India offers significant cost advantages over mature manufacturing hubs in Europe and North America. Both domestic pharmas and contract manufacturers (CMOs) are moving up the value chain into process development and drug discovery services. Many have evolved into Contract Research and Manufacturing Services (CRAMS) players.

The Top 10 Indian CMOs faced a challenging business environment in the fiscal year, 2010 – most saw revenues contract on the previous year. This report analyzes each of the Top 10 CMOs in turn, reviewing growth strategies and recent deals.

Key Features
  • Overview of the global contract manufacturing market
  • Market dynamics of Indian CMO market
  • Profile of the leading 10 players in Indian CMO/CRAMS market
  • Key contract manufacturing partnerships in the Indian CMO sector
  • Key trends and opportunities in Indian CMO market
  • Major success factors in Indian CRAMS market
  • Strategic growth analysis including SWOT profiles of leading 10 players in Indian CMO market
  • Short profile of other leading players

Key Benefits
  • Analyze the competitive positioning and outlook for each of the Top 10 Indian CMOs/CRAMS companies.
  • Develop insights on the Indian CMO market, including market size forecast, and future outlook of global CRAMS industry and opportunities in India.
  • Discover contract manufacturing deals that are shaping the development of the market.
  • Learn the key factors for success in the CMO market.
  • Understand the major issues affecting the Indian CMO industry.
  • Assess the financial performance and growth strategies of leading companies in Indian CMO market.

Key findings

The global pharmaceutical contract manufacturing market can be categorized into injectables, solid and liquid dosage forms. Solid dosage is the largest segment by revenue, but the injectable segment is expected to show greatest growth.

Asian CMOs started with large-scale manufacturing for generic and research driven companies are now acquiring assets in the US and Europe to enter the discovery and development segment of the pharmaceutical value chain.

India, riding on its cost-value proposition comprising low-cost skilled manpower and technical capabilities is strongly positioned to capture a significant portion of the growing CMO market. The CRAMS market will continue to provide high growth opportunity and companies which offer reliable services with a significant value proposition in terms of costs and technology will succeed.

India has already emerged as one of the leading cost-competitive and quality manufacturing hubs for many global players including big pharma companies. Moreover, the current economic crisis along with the continuous pricing pressure and pro-generic agenda are driving pharma companies to leverage the strengths of Indian pharma manufacturers.

Drivers of the Indian CMO market include the high number of FDA approved manufacturing facilities, large and growing talent pool and continuing cost advantages. Resistors include intellectual property concerns, competition from China, and safety concerns.

Key questions answered by this report
  • What are the key trends of Indian contract manufacturing industry?
  • Which companies will drive the future of the Indian CMO market?
  • What are the strengths, weaknesses, threats, and opportunities of the leading CMOs in India?
  • How was the financial performance of leading players in the Indian CMO market affected by the recent economic downturn?
  • Which companies are best positioned to succeed in Indian CMO market in the next five years?
  • How are the growth strategies of leading Indian CMOs such as Jubilant Organosys, Dr. Reddy’s, Divis Laboratories, Dishman, Piramal Healthcare, Hikal, Shasun, and Biocon evolving?
  • Which are the key contract manufacturing partnerships that will shape the future of Indian CMO market?
About the author
Disclaimer
Executive summary
Industry overview
Jubilant Organosys
Dr. Reddy's
AuroSource
Divis Laboratories
Dishman
Piramal Healthcare
Hikal
Shasun Chemicals and Drugs Limited (SCDL)
Biocon
Suven Life Sciences

CHAPTER 1 SCOPE

Scope
Methodology

CHAPTER 2 INDUSTRY OVERVIEW

Summary
What are CMOs?
Structure of the CMO industry
CMO expansion in Asia
Contract manufacturing and research services in context
Custom synthesis
Contract manufacturing in pharma
Key success factors for CMOs
Value addition to end-users
Scientific skill-set
Respect for intellectual property rights
Cost-effectiveness
Strong relationship with innovators
The Indian CRAMS business
Factors impacting the growth momentum of CRAMS in India
India – a biopharmaceutical manufacturing hub
Regulatory and IP issues
Key contract manufacturing/research deals in India
Future outlook of the global CRAMS industry and opportunities for India
Market dynamics
CRAMS market size and structure
Competitive landscape of the Indian CMO industry
Drivers and resistors of Indian CMOs

CHAPTER 3 JUBILANT ORGANOSYS

Summary
Company overview
Business segmentation
R&D focus
Financial performance
Growth strategies
Partnering with pharma and biotech clients
Full service provision
Diversified niche businesses reduce risks
SWOT analysis

CHAPTER 4 DR. REDDY'S

Summary
Company overview
Business segmentation
R&D focus
Financial performance
Growth strategies
mPEG alcohol manufacturing facility in Mexico
Strategic alliance with GSK for emerging markets outside India
SWOT analysis

CHAPTER 5 AUROSOURCE

Summary
Company overview
Business segmentation
R&D focus
Financial performance
Growth strategies
Aurobindo's investment in CRAMS business
Diversified contract manufacturing capabilities
SWOT analysis 56

CHAPTER 6 DIVIS LABORATORIES

Summary
Company overview
Business segmentation
R&D focus
Financial performance
Growth strategies
Innovation driven pharma companies continue to be key clients
Strong chemistry skills and process development capabilities
Generic API business to maintain steady growth
SWOT analysis

CHAPTER 7 DISHMAN

Summary
Company overview
Business segmentation
R&D focus
Financial performance
Growth strategies
CRAMS business will continue to dominate
Dishman's Solvay operation rejuvenates with its recent acquisition by Abbott
High number of capacity expansions and state-of-the-art manufacturing facilities
SWOT analysis

CHAPTER 8 PIRAMAL HEALTHCARE

Summary
Company overview
Business segmentation
R&D focus
Financial performance
Growth strategies
Strong distribution and marketing infrastructure in India
Rationalization of international contract manufacturing unit to increase its efficiency
SWOT analysis

CHAPTER 9 HIKAL

Summary
Company overview
Business segmentation
R&D focus
Financial performance
Growth strategies
Long-term contracts with leading life sciences companies
Expansion of manufacturing base by adding new plants at its FDA site
SWOT analysis

CHAPTER 10 SHASUN PHARMACEUTICALS LIMITED

Summary
Company overview
Business segmentation
R&D focus
Financial performance
Growth strategies
Manufacturing higher quantities of existing products
Integrating CRAMS offering across geographies
SWOT analysis

CHAPTER 11 BIOCON

Summary
Company overview
Business segmentation
R&D focus
Financial performance
Growth strategies
Strong manufacturing capabilities in wide range of segments
R&D collaboration with Bristol-Myers Squibb
Biopharmaceutical revenues to maintain steady growth in coming years
SWOT analysis

CHAPTER 12 SUVEN LIFE SCIENCES

Summary
Company overview
Business segmentation
R&D focus
Financial performance
Growth strategies
Certified facilities to cater for the needs of global pharmaceutical companies
Dedicated pharmaceutical product services in the form of Suven Nishtaa
SWOT analysis

CHAPTER 13 OTHER KEY PLAYERS

Summary
Lupin (Novodigm)
Company overview
Recent financial performance
Intas
Company overview
Recent financial performance
Ranbaxy (under Daiichi Sankyo)
Company overview
Recent financial performance
Wockhardt
Company overview
Recent financial performance
Strides Arcolab
Company overview
Recent financial performance
Appendix
Glossary

TABLE OF FIGURES

Figure 1: Factors influencing manufacturing outsourcing in India
Figure 2: Drivers and resistors of Indian CMOs
Figure 3: Jubilant Organosys business segmentation
Figure 4: Jubilant Organosys SWOT analysis
Figure 5: Dr. Reddy's business segmentation
Figure 6: Dr. Reddy's SWOT analysis
Figure 7: AuroSource SWOT analysis
Figure 8: Divis Laboratories SWOT analysis
Figure 9: Dishman SWOT analysis
Figure 10: Piramal Healthcare SWOT analysis
Figure 11: Hikal SWOT analysis
Figure 12: Shasun SWOT analysis
Figure 13: Biocon SWOT analysis
Figure 14: Suven SWOT analysis

TABLE OF TABLES

Table 1: Key contract manufacturing or research deals in India, 2007–10
Table 2: Indian contract manufacturing market size forecast ($bn), 2009–15
Table 3: Leading 10 CMOs/CRAMS players in India, FY 2010
Table 4: Jubilant Organosys snapshot
Table 5: Jubilant Organosys financial performance by segment ($m), FY 2010
Table 6: Jubilant Organosys pharma services financial performance by segment ($m), FY 2010
Table 7: Jubilant Organosys CRAMS financial performance by segment ($m), FY 2010
Table 8: Dr. Reddy's snapshot
Table 9: Dr. Reddy's financial performance by segment ($m), FY 2010
Table 10: AuroSource snapshot
Table 11: Divis Laboratories snapshot
Table 12: Dishman snapshot
Table 13: Dishman financial performance by segment ($m), FY 2010
Table 14: Piramal Healthcare snapshot
Table 15: Piramal Healthcare financial performance by segment ($m), FY 2010
Table 16: Hikal snapshot
Table 17: Hikal financial performance by segment ($m), FY 2010
Table 18: Shasun Pharmaceuticals Limited snapshot
Table 19: Shasun total sales ($m), FY 2010
Table 20: Shasun financial performance by key segment ($m), FY 2010
Table 21: Biocon snapshot
Table 22: Biocon financial performance by segment ($m), FY 2010
Table 23: Suven Life Sciences snapshot
Table 24: Suven financial performance by segment ($m), FY 2010
Table 25: Lupin (Novodigm) snapshot
Table 26: Intas snapshot
Table 27: Ranbaxy (now Daiichi Sankyo) snapshot
Table 28: Wockhardt snapshot
Table 29: Strides Arcolab snapshot
Table 30: Strides Arcolab financial performance by segment ($m), FY 2010
Skip to top


Ask Your Question

The top 10 CMOs in India: Market Dynamics, Competitive Positioning and Trends
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: